Neuroprotective effect of hyperbaric oxygen therapy on anterior ischemic optic neuropathy

Bat-Chen R. Avraham-Lubin1,2,‡, Olga Dratviman-Storobinsky1,‡, Shimrit Dadon-Bar El1,‡, Murat Hasanreisoglu3 and Nitza Goldenberg-Cohen1,2,4*

1 The Krieger Eye Research Laboratory, Felsenstein Medical Research Center, Petah Tiqwa, Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3 Department of Ophthalmology, Rabin Medical Center, Petah Tiqwa, Israel
4 Pediatric Unit, Schneider Children’s Medical Center of Israel, Petah Tiqwa, Israel

INTRODUCTION

Anterior ischemic optic neuropathy (AION) and pressure-induced glaucoma primarily affect the retinal ganglion cells (RGCs; Kaushik et al., 2003; Levin, 2003). Several mechanisms are known to mediate programmed death (apoptosis) of the RGCs, namely, deprivation of neurotrophic factors, alterations in gene expression, and production of reactive oxygen species. However, RGC death does not occur immediately after axonal injury, and a significant number of cells survive even several days, suggesting the involvement of pro-survival factors as well. This assumption is supported by studies showing that axotomy leads to molecular changes that underlie the regulation of cell survival may lead to innovative therapeutic methods of neuroprotection (Levin, 1999).

The mechanisms of RGC death have been examined in different models of optic nerve transection and crush (Bonfanti et al., 1996; Chaudhary et al., 1999; Kermer et al., 1999), acute retinal ischemia and reperfusion (Buchi, 1992; Adachi et al., 1996; Selles-Navarro et al., 1996), and chronic elevation of intraocular pressure (IOP; Morrison et al., 1997; Mittag et al., 2000). Recently, we characterized a rodent model of AION (rAION) wherein axonal stroke was induced by selective illumination of the optic disk in the presence of a photoactive substance (Bernstein et al., 2003; Kaushik et al., 2003). The retinal blood supply remained intact. Because the final common pathway of axonal damage is RGC death, this model made it possible to investigate the molecular changes that occur in the retina following damage to the optic nerve, with and without treatment.

The kinetics of the signaling pathways involved in apoptosis after retinal ischemia have recently been investigated (Produit-Zengaffinen et al., 2009). Extensive molecular studies revealed that members of the B-cell lymphoma 2 (Bcl-2) gene family play a critical role in the activation and control of ganglion cell death (Nickells et al., 2008) and that Bcl-2-related family members are differently regulated in the early and late phases after an ischemic retinal insult (Produit-Zengaffinen et al., 2009). Similar to primary RGC degeneration, secondary degeneration following optic nerve damage was characterized by activation of Caspase-3,
downregulation of the pro-survival genes Bcl-2 and Bcl-xL, and upregulation of the proapoptotic genes Bcl-2-associated X protein (Bax) and Bad (Levkovitch-Verbin et al., 2010).

Oxygen is a critical substrate in the alleviation of hypoxia, anoxia, and ischemia. However, it also exerts deleterious effects during reperfusion of previously ischemic tissues. Adding to this paradox is a spate of pioneering works identifying hyperoxenation (hyperoxia) and its metabolites as solely and purposefully yielding cellular and clinical benefits, particularly in ischemic reperfusion injuries (Yogaratnam et al., 2006). These effects were further improved by a novel technology, called hyperbaric oxygen (HBO), which involves the administration of oxygen at suprathermospheric pressures in high concentrations (Yogaratnam et al., 2006). Although the concept of HBO was introduced in the mid-twentieth century, it is only in the past decade or so that its therapeutic potential has been put to advantage for purposes of cellular tolerance and neuroprotection.

Hyperbaric oxygen has been found to be a useful adjunct in several models of renal, skeletal, and myocardial infarction (Yogaratnam et al., 2006), and brain ischemic reperfusion injury (Hou et al., 2007; Singhal, 2007; Solmazgul et al., 2007; Vidigal et al., 2007; Eschenfelder et al., 2008), by improving oxygen perfusion to the ischemic tissues. It currently serves as a primary or adjuvant mode of treatment for various acute or chronic disorders. Eye diseases are still among the off-label applications of HBO despite cumulative evidence of its safety and efficacy in patients with retinal artery occlusion, cystoid macular edema secondary to retinal vein occlusion, scleral thinning and necrosis after pterygium surgery, orbital rhino-cerebral mucosmyosis, non-healing corneal edema, and anterior segment ischemia (Oguz and Sobaci, 2008). Its possible benefit in some blinding diseases was noted as well. In a review of its uses in the eye, Butler et al. (2008) suggested various ocular disorders that may potentially benefit from HBO treatment, such as central retinal artery occlusion, radiation optic neuropathy, and selected cases of ischemic optic neuropathy. However, except in a few cases (Boschetti et al., 2006; Levy and Miller, 2006), findings for radiation-induced neuropathy have been disappointing (Danesh-Meyer, 2008). Beiran et al. (1995) successfully treated two patients with AION using HBO. The same group (Beiran et al., 2001) and others (Arnold and Levin, 2002) reported that when applied early, HBO improved visual outcome in patients with retinal arterial occlusion.

No methodologic investigations of HBO have been conducted to date in ischemic retinas, although earlier findings from our center highlighted the involvement of apoptosis in the cell loss consequent to central retinal artery occlusion (Goldenberg-Cohen et al., 2008). Prompted by the encouraging results in the literature, we sought to investigate the neuroprotective effect of HBO in a rAION.

RESULTS
RAION INDUCTION
Rodent model of AION was induced as previously described (Goldenberg-Cohen et al., 2003). In brief, 63 mice were anesthetized with ketamine 80 mg/kg and xylazine 4 mg/kg. A plastic custom-designed fundus corneal contact lens was used for direct in vivo visualization of the retina and optic nerve head. After intravenous administration of 0.03 mL of 2.5 mM rose bengal in phosphate-buffered saline, the optic nerve head was illuminated with argon green laser (532 nm) at the following specifications: 200 μm spot size, 50 mW power, constant duration (0.1 s). rAION was induced in the right eye of each animal; the fellow (uninjured) eye served as an internal control.

HBO TREATMENT
Immediately after rAION induction, 33 mice were placed in a HBO chamber specially designed for this experiment (Figure 1) and exposed to two sessions of 100% oxygen (2 atm) for 90 min. Thereafter treatment was repeated once daily for up to 14 days. The remaining 30 mice were untreated and served as the comparison group.

HISTOLOGICAL EXAMINATION
Sixteen mice were used for histological analysis. After euthanization at 1, 3, 7, or 21 days, both eyes were enucleated and embedded in paraffin or fixed in 4% formaldehyde, placed overnight in 30% sucrose dissolved in phosphate-buffered saline at 4˚C, and embedded in OCT compound (Tissue-Tek, sakura finerek). Three sections (6 μm each) from each eye were mounted on slides and stained with hematoxylin and eosin for light microscopy analysis.

APOPTOSIS ASSAY
Longitudinal cross-sections from the paraffin-embedded eyes were cut 6 μm thick for in situ TdT-mediated dUTP nick end-labeling assay (TUNEL; Roche Diagnostics, Mannheim,

Materials and Methods

Experimental Animals
Male wild-type C57/Bl6 mice aged 10–12 weeks were obtained for the study from Harlan Laboratories (Jerusalem). All mice were maintained and handled in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the NIH guidelines. All animal protocols were approved by the Animal Research Committee of Rabin Medical Center.

Figure 1
Hyperbaric oxygen chamber designed for mice. The mice can be seen through the windows during treatment.
Table 1 | Primer sequences used for RT-PCR analysis.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxidative-stress-induced</td>
<td>SOD-1</td>
<td>GCCCCGCCGATGAAGAAGA</td>
</tr>
<tr>
<td>Ischaemia-induced</td>
<td>HO-1</td>
<td>CAGGGCTCAGAGAACAGC</td>
</tr>
<tr>
<td>Angiogenesis-related</td>
<td>eNOS</td>
<td>GCAATGAGATCTGACTGCTCA</td>
</tr>
<tr>
<td>Apoptosis-related</td>
<td>VEGF</td>
<td>CACGACAGAAGGAGACGAA</td>
</tr>
<tr>
<td></td>
<td>Bax</td>
<td>CTGAGTGAACCAGACGCA</td>
</tr>
<tr>
<td></td>
<td>Bcl-2</td>
<td>CTTGATGACGATGACTCT</td>
</tr>
<tr>
<td></td>
<td>Bcl-xL</td>
<td>GCTCGTGGTACACCTCAG</td>
</tr>
<tr>
<td></td>
<td>Casp-3</td>
<td>ATGGGACATGAGATCAC</td>
</tr>
<tr>
<td>RGC loss</td>
<td>Thy-1</td>
<td>AAACCTTGCGGAAAGAAC</td>
</tr>
<tr>
<td>Reference gene</td>
<td>ACTB</td>
<td>TAGGACACCGGTTGAGT</td>
</tr>
</tbody>
</table>

**SOD-1**, superoxide dismutase-1; **HO-1**, heme-oxgenase-1; **eNOS**, endothelial nitric oxide synthase; **VEGF**, vascular endothelial growth factor; **Bax**, Bcl-2-associated X protein; **Bcl-2**, B-cell lymphoma 2; **Bcl-xL**, Bcl-2-like protein 1; **Casp-3**, cysteine-aspartic protease 3; **Thy-1**, thymocyte cell surface antigen-1; **ACTB**, mouse beta actin; **RGC**, retinal ganglion cell. Kindly provided by Dr. Joseph A. Garcia, from the Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Germany); results were analyzed with a fluorescence microscope (Fluoview X; Olympus, Tokyo, Japan) at 580 nm wavelength. The mean number of TUNEL-positive cells per slide was determined (three consecutive sections per slide, one slide for every 10 sections of 6 μm, total five slides per eye), with attention to the internal retinal layers. Findings were compared over time between the injured (right) and uninjured (left) eyes of the individual mice and between the injured eyes of the mice that underwent HBO treatment or were untreated.

**GENE EXPRESSION**

Forty-seven mice were used for molecular analysis. Immediately after euthanization at 1, 3, or 21 days following rAION induction, the retinas were frozen in liquid nitrogen. Total RNA was extracted with TRIzol™ reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA), followed by reverse-transcription into cDNA using random hexamers, according to the manufacturer’s protocol (Amersham Biosciences, UK), and MMLV-reverse transcriptase (Promega, Madison, WI, USA). cDNA was analyzed with real-time polymerase chain reaction (PCR) using the Sequence Detection System (ABI Prism 7900; Applied Biosystems, Foster City, CA, USA). The expression of the following genes was measured: superoxide dismutase-1 (SOD-1), heme-oxgenase-1 (HO-1), endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), Bcl-2, Bax, Bcl-2-like protein 1 (Bcl-xL), cysteine–aspartic acid protease-3 (Caspase-3), and thymocyte cell surface antigen-1 (Thy-1); cDNA input levels were normalized against mouse beta actin (ACTB). Primer pairs of the oxidative-stress-, ischaemia- and angiogenesis-related genes were kindly provided by Joseph A. Garcia, MD, PhD, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA (Scortegagna et al., 2003; Ding et al., 2005). Reactions were performed in a 20-μL volume containing 4 μL cDNA, 1 μL each of forward and reverse primers, and buffer included in the Master Mix (SYBR Green I; Applied Biosystems, Inc.). The primers are listed in Table 1. PCR cycling conditions were as follows: initial denaturation at 50°C for 2 min; followed by denaturation at 95°C for 2 min; followed by 40 cycles of denaturation at 95°C for 15 s; and annealing and extension at 60°C for 30 s. Duplicate transcriptase-based quantitative PCR (RT-QPCR) reactions were performed for each gene to minimize individual tube variability, and an average was taken for each time point. Standard curves were obtained using untreated mouse cDNA for each gene PCR assay. The results were quantified by a comparative Ct method, also known as the 2−ΔΔCt method (Giulietti et al., 2001), where:

ΔΔCt = ΔCt(sample) − ΔCt(reference).

**STATISTICAL ANALYSIS**

The results were statistically analyzed with the SPSS (SPSS Inc., Chicago, IL, USA) for Windows, version 15.0.1. Mean gene expression was compared between groups by two-way ANOVA. A P-value of less than 0.05 was considered statistically significant.

**RESULTS**

**HISTOLOGICAL CHANGES IN THE RETINA**

In the untreated rAION-injured eyes, light microscopy study revealed cell loss in the RGC layer already at 3 days following rAION induction (14% loss). Maximal loss of 27% was noted at 21 days (Figure 2).

The HBO-treated rAION eyes showed only 8% cell loss at 21 days. The inner retinal layers were slightly edematous after treatment.

**APOTOPSIS ASSAY**

On TUNEL assay of the untreated rAION-injured eyes, apoptotic RGCs were less prevalent. The HBO-treated rAION eyes showed only 8% cell loss at 21 days. The inner retinal layers were slightly edematous after treatment.
FIGURE 2 | Retinal ganglion cells apoptosis 3 days after rAION induction.  
(A) Untreated eye after rAION induction. Note the TUNEL-positive cells (red) mainly in the RGC layer. (B) HBO-treated rAION. Note the minimal apoptosis compared to (A) ×40. (C) Uninjured eye; no apoptosis.

FIGURE 3 | Retinal ganglion cells loss following rAION induction. (A) Untreated eye 21 days after rAION induction. Note the RGC loss (arrows). (B) HBO-treated eye. Note the absence of RGC loss (×40). (C) Uninjured eye (H&E).

Table 2 | Expression of oxidative-stress-induced, ischaemia-induced, and angiogenesis-related genes following rAION induction at various time points, with and without HBO treatment.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Day 1</th>
<th>Day 3</th>
<th>Day 21</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HBO-treated</td>
<td>Untreated</td>
<td>HBO-treated</td>
</tr>
<tr>
<td>Oxidative-stress-induced</td>
<td>1.16 (±0.3)*</td>
<td>0.82 (±0.2)*</td>
<td>1.00 (±0.3)</td>
</tr>
<tr>
<td>HO-1</td>
<td>0.74 (±0.4)</td>
<td>1.11 (±0.4)</td>
<td>1.20 (±0.5)</td>
</tr>
<tr>
<td>eNOS</td>
<td>0.99 (±0.3)</td>
<td>1.00 (±0.2)</td>
<td>1.10 (±0.4)</td>
</tr>
<tr>
<td>Angiogenesis-related</td>
<td>1.00 (±0.1)</td>
<td>0.88 (±0.1)</td>
<td>0.88 (±0.0)</td>
</tr>
<tr>
<td>VEGF</td>
<td>1.08 (±0.2)</td>
<td>0.81 (±0.1)</td>
<td>0.90 (±0.2)</td>
</tr>
<tr>
<td>Thy-1</td>
<td>1.00 (±0.1)</td>
<td>0.88 (±0.1)</td>
<td>0.95 (±0.1)</td>
</tr>
</tbody>
</table>

Data are expressed in percent (±SD) of levels in uninjured fellow eye.

*Statistically significant differences between HBO-treated and untreated mice with AION.

SOD-1, superoxide dismutase-1; HO-1, heme-oxygenase-1; eNOS, endothelial nitric oxide synthase; Thy-1, thymocyte cell surface antigen-1; ACTB, mouse beta actin; RGC, retinal ganglion cell.

GENE EXPRESSION

**Thy-1**

**Untreated rAION-injured eyes.** Thy-1 gene expression gradually decreased, and by 21 days after rAION induction, levels measured 73% of levels in the non-injured (left) eyes.

**HBO-treated rAION-injured eyes.** Thy-1 gene expression remained unchanged relative to levels in the uninjured eyes (NS) (Tables 2 and 3).

**SOD-1**

**Untreated rAION-injured eyes.** Expression of the oxidative-stress-induced gene, SOD-1, decreased to 82% of the level in the uninjured (left) eye on day 1 after injury (P < 0.05) and returned to the uninjured level by day 3.

**HBO-treated rAION-injured eyes.** SOD-1 gene expression increased to 116% of levels in the uninjured eyes on day 1 (P < 0.05), returned to the level in the uninjured eyes on day 3 (like...
Table 3 | Expression of apoptosis-related genes following rAION induction at various time points, with and without HBO treatment.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Day 1 HBO-treated</th>
<th>Day 1 Untreated</th>
<th>Day 3 HBO-treated</th>
<th>Day 3 Untreated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proapoptotic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caspase-3</td>
<td>0.97 ±0.29</td>
<td>0.89 ±0.15</td>
<td>1.33 ±0.44</td>
<td>1.20 ±0.28</td>
</tr>
<tr>
<td>Bax</td>
<td>1.13 ±0.46</td>
<td>1.1 ±0.5</td>
<td>1.93 ±0.9</td>
<td>1.71 ±1.28</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>1.12 ±0.49</td>
<td>1.04 ±0.19</td>
<td>1.40 ±0.55</td>
<td>1.11 ±0.3</td>
</tr>
<tr>
<td>Anti-apoptotic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bcl-1</td>
<td>1.26 ±0.41</td>
<td>1.17 ±0.39</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Bax/Bcl-1</td>
<td>1</td>
<td>1.05</td>
<td>1.38</td>
<td>1.54</td>
</tr>
<tr>
<td>Bax/Bcl-X</td>
<td>0.90</td>
<td>0.94</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

There were no statistically significant differences (P ≥ 0.05) for any of the variables between HBO-treated and untreated mice with AION.

Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; Caspase-3, cysteine-aspartic acid protease 3.

in the untreated rAION eyes), and decreased to 73% of uninjured eye levels on day 21 (NS).

HO-1 and eNOS

Untreated rAION-injured eyes. Expression of the ischemia-related genes, HO-1 and eNOS, showed no change on day 1 and decreased to 73 and 75% of levels in the uninjured (left) eyes, respectively, on day 3. On 21 days, HO-1 expression increased to 222% of levels in the uninjured eyes and eNOS levels decreased to 48% of uninjured eye levels (P = 0.01).

HBO-treated rAION-injured eyes. On day 1, HO-1 decreased to 74% of levels in the uninjured eye, whereas eNOS expression showed no change. On day 3, the expression of both genes increased, to 120 and 110% of levels in the uninjured eye, respectively (NS). On day 21, levels of HO-1 and eNOS increased to 143 and 123% (P = 0.04), respectively.

VEGF

Untreated rAION-injured eyes. VEGF decreased to 88% of levels in the uninjured eyes on day 1. On day 3, there was no change from the levels in the uninjured eyes. On day 21, levels dropped to 63% of uninjured eye levels (NS).

HBO-treated rAION-injured eyes. There was no significant change in VEGF levels at 1, 3, and 21 days after injury induction (100, 88, and 90%, respectively).

Caspase-3

Untreated rAION-injured eyes. Expression of the proapoptotic gene, Caspase-3, decreased on day 1–89% of levels in the uninjured eyes and increased on day 3–120%.

HBO-treated rAION-injured eyes. Caspase-3 levels remained at the level of the uninjured eyes on day 1 (97%) and increased to 133% of uninjured eye levels on day 3.

Bax

Untreated rAION-injured eyes. Expression of the proapoptotic Bax gene showed only a mild change (110%) on day 1 and a more significant change, to 171% of uninjured eye levels, on day 3.

HBO-treated rAION-injured eyes. Bax expression increased from 113% of uninjured eye levels on day 1 to 193% on day 3 (NS).

Bcl-2 and Bcl-X

Untreated rAION-injured eyes. Expression of the anti-apoptotic Bcl-2 and Bcl-X genes did not change on day 1. On day 3, Bcl-2 mildly increased, to 111% of uninjured eye levels (NS). The Bax/Bcl-2 ratio showed no change on day 1 and increased to 1.54 on day 3. The Bax/Bcl-x ratio showed no change on day 1 only.

HBO-treated rAION-injured eyes. Bcl-2 increased to 140% of levels in the uninjured eyes on day 3. The Bax/Bcl-2 ratio was 1.38.

DISCUSSION

The present study shows that HBO treatment is effective in preserving the RGCs after the induction of rAION. We found that injured mice treated with HBO had less cell apoptosis than untreated mice, with non-significant differences in the expression of apoptosis-related genes. We characterized the changes in genes related to oxidative-stress, ischemia, and angiogenesis in the injured retinas of the untreated and HBO-treated mice.

The rAION is a rodent model of white matter stroke, resembling central nervous system stroke, with similar characteristics to AION in humans (Bernstein et al., 2003; Goldberg-Cohen et al., 2005; Chen et al., 2008). Studies in rats have shown that oxygen, when applied early and in high doses, serves as a highly neuroprotective molecule in transient focal cerebral ischemia (Hou et al., 2007; Eschenfelder et al., 2008). These findings suggest that hyperoxia, acting via multiple direct and indirect mechanisms, could serve as a therapeutic strategy to salvage acutely ischemic central nervous system tissue. Of the available oxygen delivery methods, HBO appears to be the most potent (Singhal, 2007). Three previous clinical failures of HBO in patients with stroke (Singhal, 2007) were apparently attributable to methodologic technicalities, such as delayed time to therapy, inadequate sample size, and use of excessive chamber pressures (Singhal, 2007). Therefore, in the present study, using a model of rAION induction, we treated the mice three times within the first 24 h after AION induction and once per day thereafter for another 14 days. The chamber pressure was 2 atm, as used in the clinic.
Each group consisted of at least seven mice. Furthermore, the previous clinical trials did not assess the long-term benefit of HBO in patients with tissue reperfusion. The development of the mouse model of rAION (Bernstein et al., 2003; Goldenberg-Cohen et al., 2005, 2009), and a more recent primate model (Chen et al., 2008), has made it possible to compare the histological effect of HBO and the accompanying changes in expression of the relevant genes over time. This has important clinical implications for the combination of hyperoxygenation with neuroimaging and thrombolysis in the treatment of victims of ischemic stroke (Singhal, 2007).

The neuroprotective effect of HBO in the brain has been explained molecularly by the prevention of cell apoptosis, which in turn preserves brain tissue and promotes neurologic functional recovery (Yin et al., 2003). Our TUNEL findings of a rescue effect of HBO on the RGC in a model of optic nerve stroke are supported by an earlier study of a rodent model of focal cerebral ischaemia wherein HBO treatment abolished DNA fragmentation and reduced the number of TUNEL-positive cells in the brain (Yin et al., 2003). This diminished the infarct area and led to an improvement in neurologic scores 7 days after reperfusion. Others noted that the neuroprotective effect of HBO was dose-dependent and that HBO yielded better results than normobaric oxygen in terms of both clinical outcome and infarct volume reduction (Eschenfelder et al., 2008). Similar neuroprotective effects of HBO in ischemia-reperfusion injury were reported in skeletal muscle (Vidigal et al., 2007) and intestine (Bertoletto et al., 2007). In our study, mice underwent HBO treatment immediately after rAION induction, and then again daily for up to 14 days. We examined several upstream apoptosis factors, Bcl-2, Bcl-x, and Bax, in the mitochondrial pathways, but none of the changes following HBO treatment were statistically significant. Following the induction of retinal ischemia, as measured by an increase in IOP, some earlier studies found no change in Bcl-2 expression and protein levels (Kaneda et al., 1999), whereas others reported an increase in Bcl-2 protein levels which was maintained for at least 24 h (Produit-Zengaffinen et al., 2009). In the present study, following rAION induction, Bcl-2, and Bcl-x levels increased mildly in the untreated mice and more in the HBO-treated mice, and further increased on day 3. Bax increased on day 3 as well, more in the HBO-treated mice. This finding for the proapoptotic Bax gene is in line with previous studies in a rat model of ischemic brain (Isenmann et al., 1997). However, histologically (TUNEL assay), apoptosis decreased on days 3 and 7 in the HBO-treated eyes ($P < 0.05$), with preservation of the RGC on day 21 ($P < 0.05$). By contrast, a study of a rat model of middle cerebral artery occlusion reported no change in Bax expression and an increase in Bcl-2 (Li et al., 2009). We did not expect changes in expression of Caspase-3 gene levels, as it is activated in the protein form, although it mildly increased in both groups on day 3 (NS).

The mechanism underlying HBO-induced reduction of ischemia/reperfusion injury may involve the suppression of neurotrophil adhesion to the endothelial cell surface (Buras and Reenstra, 2007). Accordingly, prolonged inhibition of nitric oxide synthesis was found to lead to an oxidant-associated rise in neurotrophic-endothelial adhesion (Niu et al., 1994). In the present study, HBO treatment reversed the decrease in eNOS expression seen after rAION induction in the untreated mice (Table 2). Similarly, in a previous study, nitrite and nitrate content increased by 2.2-fold in rats with cardiac infarct treated with normoxia plus hyperbaria or hyperoxia plus hyperbaria, and the NOS-3 protein level increased by 1.2-fold (Cabigas et al., 2006). The authors speculated that cardioprotection was directly dependent on NOS-mediated oxygen availability.

It is not clear how HBO affects the ischemia-induced pathophysiological responses, such as angiogenesis or skeletal muscle regeneration (Asano et al., 2007). In our study, the untreated rAION mice showed an immediate decrease in VEGF levels, which resolved by day 3 but reappeared on day 21, whereas the HBO-treated mice showed only a short, non-significant reduction in VEGF levels at all time points (Table 2). These data suggest that HBO exerts a neuroprotective effect by increasing VEGF levels. Early studies of optic nerve head damage in rodents reported transient leakage in the small vessels on fluorescein angiography (Goldenberg-Cohen et al., 2005). Following severe focal cerebral ischemia, HBO reduced blood–brain barrier (BBB) damage, and edema (Veltkamp et al., 2005). However, as there is no clear vaso- genic edema in the optic nerve ischemic model, the HBO-treated mice did not show increased vascular permeability, and therefore, no significant change in VEGF levels. Other ischemic models of the hind limbs, but not the central nervous system, reported a slight increase in levels of VEGF mRNA (Asano et al., 2007), which was reversed with HBO treatment (Asano et al., 2007).

Heme-oxygenase-1 is known to exert a neuroprotective effect in ischemic conditions by regulating blood perfusion (Arai-Gaun et al., 2004). In our study, HO-1 expression increased already on day 3 after treatment. In the acute phase (day 1), HBO also prevented a decrease in SOD-1 (P < 0.05), which protects cells against oxidative-stress (Chan et al., 1994; Nishi et al., 2005). HBO-enhanced SOD-1 activity during particular periods of reperfusion has been reported in models of severe brain ischemia, indicating a potential benefit of treatment (Mrisic-Pelcic et al., 2004b). In a similar finding to ours, rats exposed to global cerebral ischemia for 20 min and treated with HBO within 6 h of reperfusion showed no change in SOD-1 expression (Mrisic-Pelcic et al., 2004a). However, unlike the present model, no treatment or delayed treatment was associated with the initial increase in SOD-1.

There are a few limitations to this study. HBO treatment was induced immediately after rAION induction, whereas in a clinical setting, treatment would likely be delayed at least by several hours if not a few days. Pilot clinical trials of neuroprotective agents have failed in part because of an inability to acquire subjects within 48 h of AION onset. Furthermore, even when given immediately after the acute event, we were not able to prove the
We have therefore described only trends, representing a possible effect of HBO treatment. However, it should be emphasized that only SOD-1 and eNOS levels were found to be significantly affected, at the early phase and the late phase, respectively, whereas none of the apoptosis-related genes showed a significant change.

CONCLUSION

Oxygenation has been widely applied in numerous experimental and clinical conditions (Barach, 2000). The main finding of this study is that in a rodent model of AION, RGC loss is reduced at 21 days after HBO treatment, suggesting that HBO may have a neuroprotective effect. Although our significant findings were limited to the histological but not the molecular effect, they may nevertheless have an important implications for the future development of treatments for acute ischemia-related visual loss in humans.

ACKNOWLEDGMENTS

We thank Dr. Joseph A. Garcia, from the Department of Internal Medicine, University of Texas Southern Medical Center, Dallas, TX, USA, for kindly providing the primer sequences for this study; Dorit Karesch for the statistical analysis; and Gloria Ginzach for editing the manuscript. This study was partially supported by the Zanvyl and Isabelle Krieger Fund, Baltimore, MD, USA and the Eldor-Metzner Clinician-Scientist Award, Chief Scientist, Ministry of Health, Israel (NGC, grant number 3–3741). This work was presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA, May 2008, and the Annual Meeting of the Israel Society for Eye and Vision Research, Neve-Ilan, Israel, March 2008. We thank Senior Technician Israel Shreger for designing and building the hyperbaric oxygen chamber.

REFERENCES


Arnold, A. C., and Levin, L. A. (2002). AION. As opposed to the histological findings, most of the molecular differences in this study were not statistically significant. We have therefore described only trends, representing a possible effect of HBO treatment. However, it should be emphasized that only SOD-1 and eNOS levels were found to be significantly affected, at the early phase and the late phase, respectively, whereas none of the apoptosis-related genes showed a significant change.

CONCLUSION

Oxygenation has been widely applied in numerous experimental and clinical conditions (Barach, 2000). The main finding of this study is that in a rodent model of AION, RGC loss is reduced at 21 days after HBO treatment, suggesting that HBO may have a neuroprotective effect. Although our significant findings were limited to the histological but not the molecular effect, they may nevertheless have an important implications for the future development of treatments for acute ischemia-related visual loss in humans.

ACKNOWLEDGMENTS

We thank Dr. Joseph A. Garcia, from the Department of Internal Medicine, University of Texas Southern Medical Center, Dallas, TX, USA, for kindly providing the primer sequences for this study; Dorit Karesch for the statistical analysis; and Gloria Ginzach for editing the manuscript. This study was partially supported by the Zanvyl and Isabelle Krieger Fund, Baltimore, MD, USA and the Eldor-Metzner Clinician-Scientist Award, Chief Scientist, Ministry of Health, Israel (NGC, grant number 3-3741). This work was presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA, May 2008, and the Annual Meeting of the Israel Society for Eye and Vision Research, Neve-Ilan, Israel, March 2008. We thank Senior Technician Israel Shreger for designing and building the hyperbaric oxygen chamber.

REFERENCES


Arnold, A. C., and Levin, L. A. (2002). AION. As opposed to the histological findings, most of the molecular differences in this study were not statistically significant. We have therefore described only trends, representing a possible effect of HBO treatment. However, it should be emphasized that only SOD-1 and eNOS levels were found to be significantly affected, at the early phase and the late phase, respectively, whereas none of the apoptosis-related genes showed a significant change.

CONCLUSION

Oxygenation has been widely applied in numerous experimental and clinical conditions (Barach, 2000). The main finding of this study is that in a rodent model of AION, RGC loss is reduced at 21 days after HBO treatment, suggesting that HBO may have a neuroprotective effect. Although our significant findings were limited to the histological but not the molecular effect, they may nevertheless have an important implications for the future development of treatments for acute ischemia-related visual loss in humans.

ACKNOWLEDGMENTS

We thank Dr. Joseph A. Garcia, from the Department of Internal Medicine, University of Texas Southern Medical Center, Dallas, TX, USA, for kindly providing the primer sequences for this study; Dorit Karesch for the statistical analysis; and Gloria Ginzach for editing the manuscript. This study was partially supported by the Zanvyl and Isabelle Krieger Fund, Baltimore, MD, USA and the Eldor-Metzner Clinician-Scientist Award, Chief Scientist, Ministry of Health, Israel (NGC, grant number 3-3741). This work was presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA, May 2008, and the Annual Meeting of the Israel Society for Eye and Vision Research, Neve-Ilan, Israel, March 2008. We thank Senior Technician Israel Shreger for designing and building the hyperbaric oxygen chamber.

REFERENCES


Arnold, A. C., and Levin, L. A. (2002). AION. As opposed to the histological findings, most of the molecular differences in this study were not statistically significant. We have therefore described only trends, representing a possible effect of HBO treatment. However, it should be emphasized that only SOD-1 and eNOS levels were found to be significantly affected, at the early phase and the late phase, respectively, whereas none of the apoptosis-related genes showed a significant change.

CONCLUSION

Oxygenation has been widely applied in numerous experimental and clinical conditions (Barach, 2000). The main finding of this study is that in a rodent model of AION, RGC loss is reduced at 21 days after HBO treatment, suggesting that HBO may have a neuroprotective effect. Although our significant findings were limited to the histological but not the molecular effect, they may nevertheless have an important implications for the future development of treatments for acute ischemia-related visual loss in humans.

ACKNOWLEDGMENTS

We thank Dr. Joseph A. Garcia, from the Department of Internal Medicine, University of Texas Southern Medical Center, Dallas, TX, USA, for kindly providing the primer sequences for this study; Dorit Karesch for the statistical analysis; and Gloria Ginzach for editing the manuscript. This study was partially supported by the Zanvyl and Isabelle Krieger Fund, Baltimore, MD, USA and the Eldor-Metzner Clinician-Scientist Award, Chief Scientist, Ministry of Health, Israel (NGC, grant number 3-3741). This work was presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA, May 2008, and the Annual Meeting of the Israel Society for Eye and Vision Research, Neve-Ilan, Israel, March 2008. We thank Senior Technician Israel Shreger for designing and building the hyperbaric oxygen chamber.


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 28 December 2010; accepted: 30 March 2011; published online: 13 April 2011.


This article was submitted to Frontiers in Neuro-ophthalmology, a specialty of Frontiers in Neurology. Copyright © 2011 Avraham-Lubin, Dravitzki-Storenboyski, Hasun-reisoglu and Goldenberg-Cohen. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.